Suvrat Bhargave
Tyrone, GANPI 1720070501
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $878,439 of the $1,072,583 with a category attached, or 81.9%. 26 manufacturers reported payments, led by AbbVie at 56.9% of the total.
Across 2,033 payments — averaging $527.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$610K
- Corium, LLC$230K
- Tris Pharma Inc$77K
- Axsome Therapeutics, Inc.$71K
- Supernus Pharmaceuticals, Inc.$39K
- Noven Pharmaceuticals, Inc.$27K
- plus $18K from 20 others
What the payments were for
- Consulting fees$35,1823%
- Speaking & faculty fees$878,43982%
- Travel & lodging$129,66312%
- Food & beverage$29,2793%
- Gifts$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 1,084 | $610,383 |
| Corium, LLC | 362 | $229,590 |
| Tris Pharma Inc | 177 | $76,611 |
| Axsome Therapeutics, Inc. | 99 | $71,394 |
| Supernus Pharmaceuticals, Inc. | 92 | $39,315 |
| Noven Pharmaceuticals, Inc. | 22 | $26,856 |
| Ironshore Pharmaceuticals Inc. | 52 | $10,063 |
| Adlon Therapeutics L.p. | 10 | $4,969 |
| Noven Therapeutics, LLC | 9 | $1,000 |
| Neos Therapeutics, LP | 21 | $412 |
| Otsuka America Pharmaceutical, Inc. | 19 | $373 |
| Teva Pharmaceuticals USA, Inc. | 16 | $299 |
| Alkermes, Inc. | 13 | $261 |
| Alfasigma USA, Inc. | 8 | $152 |
| Vertical Pharmaceuticals, LLC | 9 | $141 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $136 |
| Neurocrine Biosciences, Inc. | 5 | $136 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $129 |
| Shire North American Group Inc | 4 | $73 |
| Collegium Pharmaceutical, Inc. | 3 | $60 |
| Johnson & Johnson | 3 | $58 |
| Idorsia Pharmaceuticals US Inc | 3 | $56 |
| Lundbeck LLC | 2 | $44 |
| Bausch Health US, LLC | 2 | $37 |
| Vanda Pharmaceuticals Inc. | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$587,198
- Azstarys$224,992
- Dyanavel XR$73,658
- Auvelity$70,047
- QELBREE$34,622
- Xelstrym$27,420
- Quillichew ER$23,011
- Quillivant$15,097
- Quillivant XR$7,914
- Jornay PM 20mg capsules (Bottle of 100)$7,193
- ADHANSIA XR$4,883
- JORNAY PM$1,800
- VIIBRYD$200
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyvanseLisdexamfetamine Dimesylate | 42 | $16,415 |
| Lisdexamfetamine Dimesylate | 41 | $10,130 |
| Modafinil | 11 | $1,468 |
| Olanzapine | 16 | $999 |
| Bupropion XlBupropion Hcl | 23 | $704 |
| Zaleplon | 12 | $617 |
| Duloxetine Hcl | 31 | $464 |
| Buspirone Hcl | 30 | $443 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 13 | $433 |
| Aripiprazole | 18 | $406 |
| Escitalopram Oxalate | 29 | $403 |
| Clonazepam | 36 | $302 |
| Fluoxetine Hcl | 15 | $242 |
| Risperidone | 15 | $174 |
| Trazodone Hcl | 28 | $123 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $129 | $16,41542 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Georgiaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.